运动引起的肺动脉高血压
James J Tolle1, Aaron B Waxman, Teresa L Van Horn
1Pulmonary and Critical Care Unit, BUL 1-148, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA. jjtolle@yahoo.com
Circulation
|November 5, 2008
概括
运动引起的肺动脉高血压 (PAH) 是PAH谱的轻度早期阶段. 侵入性检测证实它是一个临床相关的条件,与静止PAH不同.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 运动生理学 运动生理学
背景情况:
- 运动引起的肺动脉高血压 (PAH) 的临床意义尚不清楚.
- 直接的血液动力学测量很少用于研究运动诱导的PAH.
研究的目的:
- 为了研究运动引起的PAH的血液动力学特征.
- 为了确定运动诱导的PAH是否代表PAH频谱内的独特的生理阶段.
主要方法:
- 对406名患者进行了侵入性心肺运动测试.
- 使用了肺和放射性动脉导管和放射性核素心室内扫描.
- 分析了血液动力学数据,以比较运动引起的PAH与静止PAH和正常对照.
主要成果:
- 与正常人相比,运动诱导的PAH (n=78) 显示了中间氧气吸收和较高的肺动脉压力和阻力.
- 压力-氧气吸收图中的"高原"模式与较低的运动能力和较高的休息肺血管阻力有关.
- 这种平原模式在休息的PAH中更常见,而"起飞"模式在正常人中更常见.
结论:
- 运动引起的PAH被确定为肺动脉高血压的频谱中的早期,轻度阶段.
- 这种情况在生理上是截然不同的,在临床上也是相关的.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...


